<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572909</url>
  </required_header>
  <id_info>
    <org_study_id>SPIRI-201</org_study_id>
    <nct_id>NCT01572909</nct_id>
  </id_info>
  <brief_title>Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With Acute Coronary Events</brief_title>
  <acronym>EMBRACE</acronym>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia (MTP-131) on Reperfusion Injury in Patients Treated With Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to assess the effectiveness, safety and tolerability of
      an investigational drug, called Bendavia, on reducing the area of heart muscle affected by a
      myocardial infarction (heart attack) in participants who have undergone successful coronary
      intervention (heart treatment) and stenting.

      Participation in the study is due to last for approximately 7 months. It is planned that up
      to 300 participants will take part in the study from centers in the United States and around
      the world.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between treatment groups of the infarct size measured by the area under the creatine kinase-MB (CK-MB)enzyme curve.</measure>
    <time_frame>Immediately after the PCI procedure and then at 6, 12, 24, 36, 48, 60, and 72 hours after the PCI.</time_frame>
    <description>Comparison is calculated from measurements from the central clinical chemistry laboratory obtained over the initial 72 hours following the initial PCI procedure from samples drawn.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the measurement of the cardiac infarct size calculated by the area under the troponin I enzyme curve.</measure>
    <time_frame>Immediately after the PCI procedure and then at 6, 12, 24, 36, 48, 60, and 72 hours after the PCI.</time_frame>
    <description>Comparison between treatment groups of the measurement of the cardiac infarct size calculated by the area under the troponin I enzyme curve calculated from measurements from the central clinical chemistry laboratory obtained over the initial 72 hours following the initial PCI procedure from samples drawn.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the measurement of the cardiac infarct size calculated by the volume of infarcted myocardium.</measure>
    <time_frame>Day 4±1</time_frame>
    <description>Comparison between treatment groups of the measurement of the cardiac infarct size calculated by the volume of infarcted myocardium (late contrast gadolinium enhancement) on the day 4±1 cardiac MRI using a 1.5-Tesla body MRI scanner. The gadolinium enhancement will be defined quantitatively by the amount of tissue exhibiting an intensity of the myocardial post-contrast signal that is more than 2 standard deviations above that in a reference region of remote, non-infarcted myocardium within the same slice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the infarct size as measured by the ratio of the volume of infarcted myocardium to the volume of edematous myocardium.</measure>
    <time_frame>Day 4±1</time_frame>
    <description>The volume of infarcted myocardium will be measured as the volume of tissue exhibiting late contrast gadolinium enhancement. This will be defined quantitatively by an intensity of the myocardial post-contrast signal that is more than 2 standard deviations above that in a reference region of remote, non-infarcted myocardium within the same slice. Standard extracellular gadolinium-based contrast agents will be used at a dose of 0.2 mmol/kg. The 2D inversion recovery prepared fast gradient echo sequences will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the degree and incidence of &quot;no-reflow&quot;.</measure>
    <time_frame>Day 4±1 and 30+7</time_frame>
    <description>Ranked in the order of priority by: The size of microvascular dysfunction, the ratio of the volume of microvascular dysfunction to the volume of ischemia, the incidence of patients with TIMI perfusion grade 3 flow after completion of the PCI, the corrected TIMI frame count at completion of the PCI, and the relative amount of ST-segment elevation resolution from the pre-PCI electrocardiogram (ECG) to the immediately post-PCI and 24-hour post-PCI ECGs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the myocardial function and structure.</measure>
    <time_frame>Day 4±1 and Day 30+7</time_frame>
    <description>Cardiac MRI by:
The left ventricular (LV) ejection fraction,
The LV end diastolic volume,
The LV end systolic volume,
The modified Hochman Choo expansion index is calculated, in which wall thicknesses are measured at the midpoint of the infarct and the septum and the sections with the thinnest infarct and most marked cavity dilation will be used for each patient. Total heart area is the cross-sectional area of the heart with left ventricle included; this ratio of dilation was used to correct for variations in patient and heart sizes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the incidence of immediate myocardial complications.</measure>
    <time_frame>24 hours post-PCI</time_frame>
    <description>Defined as:
Sustained ventricular tachycardia or ventricular fibrillation requiring medical intervention.
Q waves on ECG at 24 hours post-PCI.
Mechanical complications including Free wall rupture, Ventricular septal defect and Ischemic mitral regurgitation.
Emergency use of nitroprusside, calcium channel blocker or adenosine administration during the PCI procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics of Bendavia in acute STEMI.</measure>
    <time_frame>1, 3, 6, 12, 24, 36, 48 and 60 hours after completion of the PCI.</time_frame>
    <description>Bendavia levels will be obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the myocardial infarct size</measure>
    <time_frame>Day 30+7</time_frame>
    <description>The volume of infarcted myocardium will be calculated using late contrast gadolinium enhancement. The ratio of the volume of infarcted myocardium (late contrast gadolinium enhancement) to the volume of edematous myocardium (the ischemic volume determined by T-2 weighted images using triple inversion recovery fast spin echo sequences) will be determined. Ischemic volume will be measured by the edematous volume using T2-weighted images and a triple inversion recovery fast spin echo sequences protocol on the day 4±1 cardiac MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the laboratory markers of congestive heart failure and systemic inflammation.</measure>
    <time_frame>Pre-PCI, 24 hours after PCI, 30 + 7 days after PCI, 90 ± 14 days after PCI, 6 + 1.5 months after PCI.</time_frame>
    <description>Determined by:
N-terminal pro-B-Type natriuretic protein (NT-proBNP) levels measured at the central laboratory from samples obtained at various timepoints.
High sensitivity C-reactive protein (hsCRP) levels measured at the central laboratory from samples obtained at</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of the comparative impact of Bendavia through 30 days and 6 months on the incidence of the composite endpoint.</measure>
    <time_frame>Through 30 days and 6 months</time_frame>
    <description>Comparison includes the following events:
Death (all causes).
New onset CHF beginning &gt;24 hours after PCI but within the duration of the index hospitalization.
CHF re-hospitalization after discharge from index hospitalization to 6 months later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between treatment groups of renal function.</measure>
    <time_frame>Through 30 days and through 6 months</time_frame>
    <description>Serial determinations of serum creatinine, estimated GFR (using the Modified Diet Renal Disease formula), cystatin C, and BUN through 30 days.
Serial calculations of estimated GFR (using the Modified Diet Renal Disease formula) through 30 days and through 6 months.
Incidence of at least a grade 1 episode of contrast-induced nephropathy post-PCI, defined as an increase in serum creatinine of ≥25% of the baseline value and/or an increase in serum creatinine of 0.5 mg/dl occurring within 48 hours of receiving a radiographic contrast agent through 30 days and through 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Reperfusion Injury</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Bendavia™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendavia (MTP-131)</intervention_name>
    <description>0.05 mg/kg/hr</description>
    <arm_group_label>Bendavia™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identically appearing placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 and &lt;85 years

          -  The patient presents with first-time acute, anterior wall STEMI scheduled to undergo
             primary PCI and stenting.

          -  The patient has symptoms of cardiac ischemia of ≥10 minutes.

          -  The patient must demonstrate an anterior wall STEMI with &gt;0.1 mV ST-segment elevation
             in at least two contiguous precordial leads (i.e., V1-V4) or presumed new left bundle
             branch block.

          -  The time from onset of symptoms of cardiac ischemia to the anticipated time of initial
             PCI balloon inflation does not exceed four (4) hours and it is anticipated that the
             door-to-balloon time will be &lt;2 hours.

          -  For female patients of child-bearing potential, an adequate form of contraception must
             be adhered to prior to entry into the study and for a further 3 months after the
             follow-up visit. Female patients of childbearing potential must have a negative serum
             pregnancy test prior to entry into the study.

          -  Female patients not of childbearing potential (i.e. female patients who are
             postmenopausal since last regular menses, or have been surgically sterilized at least
             1 year prior to screening visit) are eligible to enter the study.

          -  For male patients with female partners of child-bearing potential, an adequate form of
             contraception must be adhered to prior to entry into the study and for a further 3
             months after the post-study medical.

          -  Written informed consent obtained that strictly adheres to the written guidelines from
             the local Institutional Review Board (IRB)/ Ethical Committee (EC).

        Exclusion Criteria

          -  Cardiogenic shock or maximal systolic blood pressure (BP) &lt;80 mm Hg after fluid and/or
             vasopressor resuscitation on at least two consecutive readings.

          -  Ongoing vasopressor support.

          -  Uncontrolled hypertension defined as a systolic BP &gt;180 mm Hg or a diastolic BP &gt;110
             mm Hg on at least two consecutive readings.

          -  Cardiac arrest or arrhythmia requiring prolonged (&gt;5 minutes) chest compressions/
             cardiopulmonary resuscitation (CPR).

          -  Prior coronary artery bypass graft surgery (CABG).

          -  Prior myocardial infarction (MI).

          -  Implantable cardioverter-defibrillator (ICD) or permanent pacemaker (PPM) unless known
             to be MRI safe. The presence of an MRI-compatible pacemaker or other MRI-compatible
             hardware will not be a contraindication to participation in this trial.

          -  Known left ventricular ejection fraction &lt;30% prior to the qualifying infarct.

          -  History of clinically significant hepatic disturbance or chronic renal impairment at
             the time of admission.

          -  Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the last 30
             days.

          -  Any known disorder that is associated with immunologic dysfunction (e.g., cancer,
             lymphoma, a positive serologic test for the human immunodeficiency virus, or
             hepatitis) more recently than 6 months before presentation or the administration of
             immunosuppressive drugs within 10 days of the STEMI at doses expected to be associated
             with immunosuppression including high dose steroids (&gt;2.5 mg/d hydrocortisone or equal
             potency of synthetic steroids), TNF-α blockers or methotrexate/azathioprine.

          -  Any condition that, in the Investigator's opinion, would prevent adherence to the
             requirements of the protocol including language barrier or current alcohol or drug
             abuse.

          -  Contraindications (including claustrophobia) to cardiac MRI at study entry.

          -  Participation in an investigational drug or device study within the 30 days prior to
             enrollment into the EMBRACE-STEMI Trial or anticipated within the next 4 days.

          -  Female patients who are pregnant or breastfeeding during the study or intend to within
             30 days of receiving study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anjan Chakrabarti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Interventional Cardiology, 185 Pilgrim Rd, Baker 4, Boston, MA 02215</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. M. Gibson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center, Interventional Cardiology, 185 Pilgrim Rd, Baer 4, Boston, MA 02215</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Medical Research Center</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton Cardiac Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin, Charité Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhaus Klinikum Eifel</name>
      <address>
        <city>Bitburg</city>
        <zip>54634</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Herford</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus Kardiologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal, Herzzentrum Elberfeld</name>
      <address>
        <city>Wuppertal</city>
        <zip>42117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gottsegen Gyorgy Orszagos Kardiologiai Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Kardiológiai Központ, Városmajor u. 68</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Honvédkórház-Állami Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE Klinikai Központ Szívgyógyászati Klinika</name>
      <address>
        <city>Pecs</city>
        <zip>H-7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent György Kórház, II. Belgyógyászati Osztály</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>H-8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Kórház, Kardiológiai Osztály, Zrínyi Miklós út 1.</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>H-8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pwla II, Centrum Interwencyjnego Leczenia Chorob Serca i Naczyn z Pododdzialem Kariologii Interwencyjnej</name>
      <address>
        <city>ul. Pradnicka 80</city>
        <state>Krakow</state>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Pracownia Kardiologii Inwazyjnej</name>
      <address>
        <city>ul. Banacha 1A</city>
        <state>Warsaw</state>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPSK Nr 7 Klaskiego Uniwersytetu Medycznego w Katowicach, Gornoslaskie Centrum Medyczne im. Prof. Leszka Gieca, III Oddzial Kardiologii, Zklad Kardiologii Inwazjnejul, Ziolowa 45-47</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPSK Nr 7 Slaskiego Uniwersytetu Medycznego w Katowicach, Gornoslaskie Centrum Medyczne im. Prof. Leszaka Gieca, I Oddzial Kardiologii, ul. Ziolowa 45-47</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony w Kielcach, Swietokrzyskie Centrum Kardiologii</name>
      <address>
        <city>Kielce</city>
        <zip>25-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im WI. Bieganskiego, II Katedra i Klinika Kardiologii Uniwersytetu Medycznego w Lodzi, Pracownia Kardiologii Inwazyinej, ul. Kniaziewicza 1/5</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Wojewodzkie Centrum Medyczne, Zaklad Diagnostyki Obrazowej, AI. W. Witosa 26</name>
      <address>
        <city>Opole</city>
        <zip>45-418</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii</name>
      <address>
        <city>Oswiecim</city>
        <zip>32-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Bielanski im. ks. Jerzego Popieluszki</name>
      <address>
        <city>Warsaw</city>
        <zip>01-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii im. Prymasa Tysiaclecia Stefana Kardynala Wyszynskiego</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnoslaski Szpital Specjalistyczny im. T. Marciniaka, Centrum Medycyny Ratunkowe</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-420</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Specjalistyczny we Wroclawiu, Oddzial Kardiologiczny, ul. H. Kamieskiego 73a</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Wojewodzki im. Papieza Jana Pawla II w Zamosciu, Oddzial Kardiologii z Pododdzialem Intensywnej Terapil Kardiologicznej, ul. Aleje Jana Pawta II 10</name>
      <address>
        <city>Zamosc</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <disposition_first_submitted>November 11, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 11, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 10, 2015</disposition_first_posted>
  <last_update_submitted>November 11, 2015</last_update_submitted>
  <last_update_submitted_qc>November 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Reperfusion</keyword>
  <keyword>Primary PCI</keyword>
  <keyword>Stenting for ST-segment Elevation Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

